| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Karolinska Institutet (Drs. Almkvist, Guan, Svensson, Hellström–Lindahl, and Nordberg, and T. Darreh–Shori), and Geriatric Clinic (Drs. Almkvist, Garlind, and Nordberg, and B. Strandberg), Huddinge University Hospital, Stockholm, Sweden; and Hebrew University of Jerusalem (Dr. Soreq), Israel.
Address correspondence and reprint requests to Dr. Agneta Nordberg, Karolinska Institutet, NEUROTEC, Division of Molecular Neuropharmacology, Huddinge University Hospital, B84, S-141 86 Stockholm, Sweden; e-mail: Agneta.Nordberg{at}neurotec.ki.se
Objective: To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD.
Methods: Eleven patients with mild AD received rivastigmine for 12 months. Cholinesterase (ChE) activities in the CSF and plasma were assessed colorimetrically. Immunoblot analysis was used to evaluate AChE isoforms. Neuropsychiatric tests were performed throughout the study.
Results: At 12 months, the mean dose of rivastigmine was 8.6 mg/d and specific activities of ChE in the CSF were lower than baseline values (by 36% for AChE and 45% for BuChE), correlating with parallel reductions in the plasma (27% for AChE and 33% for BuChE). The reduction of specific activities in the CSF, but not in the plasma, appeared to be dependent on the dose and duration of treatment. Scores of some of the neuropsychological tests associated with memory and attention were correlated with both plasma and CSF AChE and BuChE inhibition for up to 6 months. Immunoblot analysis revealed up-regulation of the "read-through" AChE isoform (AChE-R), whereas levels of the synaptic isoform were unchanged.
Conclusions: Rivastigmine causes persistent inhibition of AChE and BuChE in CSF as well as plasma. The persistent CSF inhibition contrasts with earlier findings after long-term treatment by the reversible ChE inhibitor tacrine, which demonstrated increased AChE activity in the CSF but not in the blood. Rivastigmine’s effects on the preferential up-regulation of the AChE-R isoform may have a favorable effect on disease stabilization.
This article has been cited by other articles:
|
|
 |
|
  G. Lefevre, M. Buche, G. Sedek, S. Maton, A. Enz, U. Lorch, C. Sagan, and S. Appel-Dingemanse Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch J. Clin. Pharmacol., April 1, 2009; 49(4): 430 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H Feldman, R. Lane, and on behalf of the Study 304 Group Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, October 1, 2007; 78(10): 1056 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Oertel, J. S. Ross, K. Eggert, and G. Adler Rationale for transdermal drug administration in Alzheimer disease Neurology, July 24, 2007; 69(4_suppl_1): S4 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Ellis Cholinesterase Inhibitors in the Treatment of Dementia J Am Osteopath Assoc, March 1, 2005; 105(3): 145 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Birikh, E. H. Sklan, S. Shoham, and H. Soreq Interaction of "readthrough" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior PNAS, January 7, 2003; 100(1): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Farchi, H. Soreq, and B. Hochner Chronic acetylcholinesterase overexpression induces multilevelled aberrations in mouse neuromuscular physiology J. Physiol., January 1, 2003; 546(1): 165 - 173. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
